<DOC>
	<DOC>NCT02103478</DOC>
	<brief_summary>This 2-stage, open-label study will evaluate safety and pharmacokinetics of ASTX727, as well as determine the dose for the study's second stage. In the second stage the selected dose will be confirmed and evaluated for clinical activity, including response rate.</brief_summary>
	<brief_title>Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS</brief_title>
	<detailed_description>Dose levels for the study's second stage will be based on safety and pharmacokinetics.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>IPSS low, intermediate 1, intermediate2, or high risk MDS (including CMML) in Dose Escalation and Dose ConfirmationRandomization; only intermediate2, or high risk MDS in Dose ConfirmationOpen Label ECOG 0 to 2 No major surgery within 2 weeks of starting study treatment No cytotoxic chemotherapy within 2 weeks of starting study treatment Able to swallow pills Previous treatment with 2 or more courses of decitabine (all stages) or azacitidine (Dose Confirmation stage only) Treatment with investigational therapy within 2 weeks of study treatment Uncontrolled medical disease(s) or active, uncontrolled infection Diagnosed with AML Active uncontrolled gastric or duodenal ulcer Known history of HIV or hepatitis C or B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>